Post by MPN-MATE Admin » Wed Jan 29, 2020 10:14 am
Hey all... 
I simply found this an optimistic and encouraging from the perspective of MF sufferers, and especially if & when their Ruxolitinib (aka Jakafi), loses some of its efficacy, which it tends to do after circa 3.2 years...
It talks a little about some newer developments also, other than 'Inrebic' (Fedratinib)... It is also really important to note the Big *WARNING* That comes with Fedratinib:
The approval of fedratinib comes with an FDA Boxed Warning for serious and fatal encephalopathy, including Wernicke's encephalopathy
On the other hand, Imetelstat is showing some interesting promise for transfusion & people who are badly affected by anaemia...
Imetelstat has already gained fast track designation by the FDA in myelofibrosis and myelodysplastic syndrome. It appears to have the ability to reduce the need for transfusions. For the patient who is dealing with anemia and transfusion-dependency rather than spleen-related symptoms, imetelstat may be the drug for them
Definitely worth a read...
Best wishes
Steve
Treatment options
Ruxolitinib at last
New meds for Myelofibrosis 
Treatment options in Scotland for PV....
ET - Peg shortage alternative treatment options
